Work

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Year: 2017

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood.v130.suppl_1.640.640

Authors: Amer M. Zeidan, Rachel J. Cook, Rodolfo Bordoni, Ekaterine Asatiani, Gongfu Zhou, Théa Faivre, Michael Byrne, Michael R. Savona

Institutions: Yale Cancer Center, Yale University, OHSU Knight Cancer Institute, Georgia Cancer Specialists, Incyte (United States), Vanderbilt University Medical Center

Language: English

Topic: Cytokine Signaling Pathways and Interactions

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2785169786

Cites:

Cited by: 4

Related to: 10